Cat. No.: HY-10072

SPC 839

Customer Review

Based on 1 Customer Validation

SPC 839 (compound 10) is an orally active inhibitor of AP-1 and NF-kB mediated transcriptional activation with IC₅₀ of 0.008 μM.

For research use only. We do not sell to patients.

Purity: 99.86%
CAS No.: 219773-55-4
Formula: C₁₈H₁₄N₄O₃S
Molecular Weight:366.39

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SPC 839 Chemical Structure

CAS No.: 219773-55-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

SPC 839 (compound 10) is an orally active inhibitor of AP-1 and NF-kB mediated transcriptional activation with IC₅₀ of 0.008 μM^[1].

All NF-κB Isoforms :

All AP-1 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	IC₅₀	618 nM Compound: 26; AS602868	Inhibition of wild type FLT3 (unknown origin) expressed in mouse BAF3 cells Inhibition of wild type FLT3 (unknown origin) expressed in mouse BAF3 cells	[PMID: 31207462]
HUVEC	EC₅₀	0.38 μM Compound: 30	Potentiation of TNF-alpha-induced NF-kappaB p65 nuclear translocation in HUVEC cells by immunostaining Potentiation of TNF-alpha-induced NF-kappaB p65 nuclear translocation in HUVEC cells by immunostaining	[PMID: 19136257]
HUVEC	EC₅₀	1.6 μM Compound: 30	Induction of NF-kappaB p65 nuclear translocation in HUVEC cells by immunostaining Induction of NF-kappaB p65 nuclear translocation in HUVEC cells by immunostaining	[PMID: 19136257]
HUVEC	IC₅₀	2 μM Compound: 3	Inhibition of TNFalpha stimulated human NF-kappaB-mediated beta lactamase gene expression in HUVEC Inhibition of TNFalpha stimulated human NF-kappaB-mediated beta lactamase gene expression in HUVEC	[PMID: 18024113]
Jurkat	EC₅₀	38 nM Compound: 7; SPC-839	Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay	[PMID: 39005064]
Jurkat	IC₅₀	0.008 μM Compound: 42, SPC-839	Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	[PMID: 24831826]
Jurkat	IC₅₀	0.008 μM Compound: 42, SPC-839	Inhibition of NF-kappaB-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay Inhibition of NF-kappaB-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	[PMID: 24831826]
Jurkat	IC₅₀	0.008 μM Compound: 10	Inhibition of AP-1 and NF-kB mediated transcriptional activation in Jurkat T-cells Inhibition of AP-1 and NF-kB mediated transcriptional activation in Jurkat T-cells	[PMID: 14592511]
RAW264.7	IC₅₀	3.32 μM Compound: SPC-839	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced TNF-alpha production Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced TNF-alpha production	[PMID: 24813730]
RAW264.7	IC₅₀	4.41 μM Compound: SPC-839	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production	[PMID: 24813730]

In Vivo

SPC 839 (compound 10) (30 mg/kg, p.o., 21 days) shows significant activity in adjuvant-induced arthritis rat model, reducing uninjected foot swelling by 65%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 219773-55-4
Appearance Solid
Molecular Weight 366.39
Formula C₁₈H₁₄N₄O₃S
Color White to off-white
SMILES

O=C(C(C)=C1)N(NC2=C(C(OC)=CC=C3)C3=NC(C4=CC=CS4)=N2)C1=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (272.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7293 mL

13.6467 mL

27.2933 mL

5 mM

0.5459 mL

2.7293 mL

5.4587 mL

10 mM

0.2729 mL

1.3647 mL

2.7293 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Moorthy S S Palanki, et al. The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4077-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7293 mL	13.6467 mL	27.2933 mL	68.2333 mL
	5 mM	0.5459 mL	2.7293 mL	5.4587 mL	13.6467 mL
	10 mM	0.2729 mL	1.3647 mL	2.7293 mL	6.8233 mL
	15 mM	0.1820 mL	0.9098 mL	1.8196 mL	4.5489 mL
	20 mM	0.1365 mL	0.6823 mL	1.3647 mL	3.4117 mL
	25 mM	0.1092 mL	0.5459 mL	1.0917 mL	2.7293 mL
	30 mM	0.0910 mL	0.4549 mL	0.9098 mL	2.2744 mL
	40 mM	0.0682 mL	0.3412 mL	0.6823 mL	1.7058 mL
	50 mM	0.0546 mL	0.2729 mL	0.5459 mL	1.3647 mL
	60 mM	0.0455 mL	0.2274 mL	0.4549 mL	1.1372 mL
	80 mM	0.0341 mL	0.1706 mL	0.3412 mL	0.8529 mL
	100 mM	0.0273 mL	0.1365 mL	0.2729 mL	0.6823 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SPC 839

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Clinical Compound Library

Anti-Aging Compound Library

All NF-κB Isoforms

All AP-1 Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

SPC 839 Related Classifications

HY-10072 Related Classifications